ÐÂÎÅÖÐÐÄ
News Center
Á¢ÒìÍŽᣡbevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾±´ÄªËհݵ¥¿¹ÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆÉöϸ°û°©ÉÏÊÐÉêÇë»ñÊÜÀí
Ðû²¼Ê±¼ä£º2024-08-02
8ÔÂ1ÈÕ£¬£¬£¬£¬£¬£¬£¬Öйú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐĹÙÍøÏÔʾ£¬£¬£¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾£¨1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇç×ÔÖ÷Ñз¢µÄÁ¢ÒìÉúÎïÒ©±´ÄªËհݵ¥¿¹×¢ÉäҺ͎áÁ¢ÒìÒ©ÑÎËá°²ÂÞÌæÄὺÄÒµÄÐÂ˳Ӧ֢ÉÏÊÐÉêÇëÒÑ»ñÊÜÀí£¬£¬£¬£¬£¬£¬£¬ÓÃÓÚÒ»ÏßÖÎÁÆÍíÆÚ²»¿ÉÇгý»òתÒÆÐÔÉöϸ°û°©£¨RCC£©¡£¡£¡£¡£¡£¡£¡£¡£ÕâÊDZ´ÄªËհݵ¥¿¹×¢ÉäÒºÉ걨ÉÏÊеĵÚÈý¸ö˳Ӧ֢£¬£¬£¬£¬£¬£¬£¬ÊÇÑÎËá°²ÂÞÌæÄὺÄÒÉ걨ÉÏÊеĵڰ˸ö˳Ӧ֢¡£¡£¡£¡£¡£¡£¡£¡£±¾´ÎÐÂ˳Ӧ֢µÄÉÏÊÐÉêÇëÒ²ÊǺ£ÄÚÊ×´ÎʹÓÃË«¹ú²úÁ¢ÒìÒ©×éºÏÒ»ÏßÃâÒßÖÎÁÆÍíÆÚÉöϸ°û°©¡£¡£¡£¡£¡£¡£¡£¡£
Éö°©ÊÇÃÚÄòϵͳ×î³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò»£¬£¬£¬£¬£¬£¬£¬RCCÕ¼ËùÓÐÉö°©²¡ÀýµÄ80%~90%[1]¡£¡£¡£¡£¡£¡£¡£¡£¾Ýͳ¼Æ£¬£¬£¬£¬£¬£¬£¬2022ÄêÖйúÉö°©Ð·¢²¡ÀýºÍéæÃü²¡Àý»®·ÖԼΪ7.7ÍòÀýºÍ4.6ÍòÀý[2]¡£¡£¡£¡£¡£¡£¡£¡£Ô¼Èý·ÖÖ®Ò»µÄÉö°©»¼ÕßÔÚ³õÕïʱÒѱ¬·¢Ö×ÁöÔ¶´¦×ªÒÆ£¬£¬£¬£¬£¬£¬£¬¶ø¾ÖÏÞÐÔ»¼Õß½ÓÊÜÉöÇгýÊõºóÈÔÓÐ20-50%·ºÆðÖ×ÁöÔ¶´¦×ªÒÆ[3,4]¡£¡£¡£¡£¡£¡£¡£¡£
ETER100Ñо¿£¨NCT04523272£©ÊÇÒ»ÏîËæ»ú¡¢¿ª·Å¡¢ÑôÐÔÒ©ÎïƽÐбÈÕÕ¡¢¶àÖÐÐÄIIIÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬£¬£¬Ö¼ÔÚÆÀ¹À±´ÄªËհݵ¥¿¹ÍŽáÑÎËá°²ÂÞÌæÄὺÄҺͱÈÕÕ×éÒ»ÏßÖÎÁÆÍíÆÚ²»¿ÉÇгý»òתÒÆÐÔRCCµÄÓÐÓÃÐÔºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£¡£Ñо¿ÏÔʾ£¬£¬£¬£¬£¬£¬£¬Ïà½ÏÓÚ±ÈÕÕ×飬£¬£¬£¬£¬£¬£¬±´ÄªËÕ°ÝÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆÍíÆÚRCC¿ÉÏÔÖø½µµÍ»¼Õߵļ²²¡Ï£Íû»òéæÃüΣº¦£¬£¬£¬£¬£¬£¬£¬Í¬Ê±¸ÄÉÆORR¡¢OSµÈ´ÎÒªÖյ㡣¡£¡£¡£¡£¡£¡£¡£¹ØÓÚÏêϸµÄÑо¿Êý¾Ý£¬£¬£¬£¬£¬£¬£¬¹«Ë¾½«ÔÚ½üÆÚ¹ú¼ÊѧÊõ´ó»áÉÏÐû²¼¡£¡£¡£¡£¡£¡£¡£¡£
´ËÇ°£¬£¬£¬£¬£¬£¬£¬°²ÂÞÌæÄá»ñ¡¶CSCOÉö°©ÕïÁÆÖ¸ÄÏ2023¡·ÍƼöÓÃÓÚתÒÆÐÔ»ò²»¿ÉÇгýÐÔ͸Ã÷ϸ°ûÉöϸ°û°©µÄÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬Ëæ×ÅÁÙ´²¿ª·¢Ò»Ö±Ç¿»¯£¬£¬£¬£¬£¬£¬£¬°²ÂÞÌæÄáÍŽᱴĪËհݵ¥¿¹ÓÐÍûΪÍíÆÚÉö°©ÃâÒßÖÎÁÆÌṩеÄ˼Ð÷¡£¡£¡£¡£¡£¡£¡£¡£½üÄêÀ´£¬£¬£¬£¬£¬£¬£¬bevictorΰµÂ¹ÙÍø - ΤµÂ¹Ù·½ÍøÕ¾ÖÂÁ¦Á¢Ò죬£¬£¬£¬£¬£¬£¬ÔÚÖ×ÁöÁìÓòÖð²½¹¹½¨ÆðÒÔ°²ÂÞÌæÄáΪ½¹µã£¬£¬£¬£¬£¬£¬£¬PD-1/PD-L1ΪÁ½ÒíµÄÇ¿Ê¢²úÆ·¾ØÕ󡣡£¡£¡£¡£¡£¡£¡£Î´À´£¬£¬£¬£¬£¬£¬£¬¹«Ë¾½«¼ÌÐøÍƽø±´ÄªËհݵ¥¿¹ºÍ°²ÂÞÌæÄáµÄÁÙ´²¿ª·¢£¬£¬£¬£¬£¬£¬£¬¿ªÍØ˳Ӧ֢½á¹¹£¬£¬£¬£¬£¬£¬£¬ÒÔÆÚΪ¸ü¶à°©Ö¢»¼Õß´øÀ´»ñÒæ¡£¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1.ÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÎÀÉú¿µ½¡Î¯Ô±»á.¡¶Éöϸ°û°©ÕïÁÆÖ¸ÄÏ£¨2022Äê°æ£©¡·.2022.
2.Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022;135:584-90.
3.Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol 2020;11:79-87.
4.Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.
ÉùÃ÷£º
1. ±¾ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬£¬£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬£¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£¡£¡£
2. ±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£¡£¡£
3. ±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬£¬£¬£¬£¬²»¿ÉÒÔÈκη½·¨È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬£¬£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡£¡£¡£¡£¡£¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬£¬°üÀ¨Óйء¾±´ÄªËհݵ¥¿¹×¢ÉäÒº¡¢ÑÎËá°²ÂÞÌæÄὺÄÒ¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢ÉÌÒµ»¯Õ¹Íû¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡£¡£¡£¡£¡£¡£¡£“Ô¤ÆÚ”¡¢“ÐÅÍД¡¢“¼ÌÐø”¡¢“¿ÉÄÜ”¡¢“Ô¤¼Æ”¡¢“ÆÚÍû”¡¢“ÓÐÍû”¡¢“ÍýÏ딡¢“ÍýÏ딡¢“DZÔÚ”¡¢“Õ¹Íû”¡¢“Ô¤¼Æ”¡¢“Ó¦¸Ã”¡¢“½«”¡¢“Ä┡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡£¡£¡£¡£¡£¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÕ¹Íû»òÆÚÍû£¬£¬£¬£¬£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢Ñз¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»òΣº¦µÄÓ°Ï죬£¬£¬£¬£¬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡£¡£¡£¡£¡£¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄΣº¦£¬£¬£¬£¬£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬£¬£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡£¡£¡£¡£¡£¡£¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬£¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡£¡£¡£¡£¡£¡£¡£